Development of a straightforward and sensitive scale for MCI and early AD clinical trials

Although the Clinical Dementia Rating Scale‐Sum of Boxes score (CDR‐SB) is a widely accepted and commonly used global scale, validated clinical endpoints of cognitive changes are unavailable in the predementia stages of Alzheimer's disease (AD), and a new clinical assessment with reliability and sensitivity is needed in the mild cognitive impairment (MCI) population.

[1]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[2]  J. Hobart,et al.  Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory , 2013, Alzheimer's & Dementia.

[3]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[4]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[5]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[6]  S. Hendrix,et al.  Introducing a new tool for optimizing responsiveness to decline in early Alzheimer's disease , 2012, Alzheimer's & Dementia.

[7]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[8]  Pedro Rosa-Neto,et al.  Performance testing of a fully automated, Chemiluminescent, beta-amyloid 42 assay , 2013, Alzheimer's & Dementia.

[9]  Andrew C. Hooker,et al.  Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling , 2014, Pharmaceutical Research.

[10]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[11]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[12]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[13]  Nandini Raghavan,et al.  The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials , 2013, Alzheimer's & Dementia.

[14]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[15]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[16]  Michael Weiner,et al.  Early Indications of Future Cognitive Decline: Stable versus Declining Controls , 2013, PloS one.

[17]  Viswanath Devanarayan,et al.  Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis: Prediction of Conversion From Mild Cognitive Impairment to Alzheimer Disease , 2011, Alzheimer disease and associated disorders.

[18]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[19]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[20]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[21]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[22]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .